Pacific Biosciences of California, Inc. - Common Stock (PACB)
1.2250
+0.0050 (0.41%)
Pacific Biosciences is a biotechnology company that specializes in developing advanced sequencing technologies designed to enable detailed analysis of genetic material
The company's innovative platforms are used for applications such as genomics research, clinical diagnostics, and personalized medicine, providing researchers and healthcare professionals with powerful tools for understanding complex biological systems. Their technology focuses on real-time, high-fidelity sequencing, allowing for the detection of genetic variations that traditional methods may miss, thereby contributing to significant advancements in the fields of genomics and molecular biology.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQPACB) and its peers.
Via StockStory · March 17, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 6.8%. This performance was disappointing since the S&P 500 climbed 1%.
Via StockStory · March 11, 2025

Via Benzinga · February 14, 2025

Via Benzinga · January 23, 2025

Via Benzinga · August 28, 2024

Genomics company Pacific Biosciences of California (NASDAQPACB) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP loss of $0.20 per share was 15.5% below analysts’ consensus estimates.
Via StockStory · February 13, 2025

Genomics company Pacific Biosciences of California (NASDAQPACB) will be announcing earnings results tomorrow after market hours. Here’s what investors should know.
Via StockStory · February 12, 2025

With Ark Invest ending 2024 on a strong note, the aggressive growth icon is hoping to build on that momentum in 2025.
Via The Motley Fool · January 7, 2025

Cathie Wood is investing in PacBio, a biotech company with potential for genomics revolution. ARK Invest is confident in its long-term growth.
Via Benzinga · December 5, 2024

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.
Via MarketBeat · November 16, 2024

The rock star money manager is starting to roll with the rallying market.
Via The Motley Fool · November 12, 2024

Via Benzinga · November 8, 2024

Via Benzinga · October 14, 2024

Via Benzinga · October 14, 2024

Via Benzinga · October 11, 2024

Via Benzinga · October 11, 2024

Via Benzinga · October 11, 2024

It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.
Via Talk Markets · September 23, 2024